Potential of non-FDG PET radiotracers for paediatric patients with solid tumours
Molecular imaging with positron emission tomography (PET) offers significant potential for improving diagnostic accuracy, staging and treatment monitoring in paediatric solid tumours, by using radiopharmaceuticals more specific than [18F]fluorodeoxyglucose ([18F]FDG). While non-[18F]FDG tracers have...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | EJC Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772610X24000631 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850061470522408960 |
|---|---|
| author | Leonor Teles Nelleke Tolboom Sabine L.A. Plasschaert Alex J. Poot Arthur J.A.T. Braat Max M. van Noesel |
| author_facet | Leonor Teles Nelleke Tolboom Sabine L.A. Plasschaert Alex J. Poot Arthur J.A.T. Braat Max M. van Noesel |
| author_sort | Leonor Teles |
| collection | DOAJ |
| description | Molecular imaging with positron emission tomography (PET) offers significant potential for improving diagnostic accuracy, staging and treatment monitoring in paediatric solid tumours, by using radiopharmaceuticals more specific than [18F]fluorodeoxyglucose ([18F]FDG). While non-[18F]FDG tracers have already improved diagnostic abilities in adult solid cancers such as prostate and neuroendocrine tumours, their use in the paediatric population has been underexplored. This narrative review summarises clinical evidence regarding the use, advantages, and limitations of these more specific PET tracers in paediatric patients. In neuroblastoma, [18F]mFBG, [18F]F-DOPA, and SSTR-targeting peptides stand out as the most evolved and promising tracers for the clinical setting, with encouraging results regarding feasibility, safety and detection rates. SSTR-targeting peptides have also consistently outperformed other imaging methods (both conventional and functional) and carry the benefits of theragnostic applications. For brain tumours, amino acid-based tracers in general stand out due to their ability to surpass the blood-brain barrier/blood-tumour barrier (BBB/BTB) and their specific accumulation in malignant tissue. Other paediatric solid tumours, such as sarcoma and bone tumours, suffer from a clear lack of clinical evidence that should be addressed in the near future. The studies performed to date show high accuracy, evident prognostic value, and significant clinical impact of non-[18F]FDG tracers in paediatric patients with solid tumours. However, prospective studies with longer follow-up times are warranted to provide high-level evidence regarding the impact of these tracers on patient management and prognosis, to consolidate the encouraging results obtained so far. Further research and international collaboration will be essential to overcome current challenges related to low incidence of paediatric solid tumours, logistical barriers and concerns about radiation exposure. |
| format | Article |
| id | doaj-art-c957bee80bbc48288e68cd4717e83cd2 |
| institution | DOAJ |
| issn | 2772-610X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Paediatric Oncology |
| spelling | doaj-art-c957bee80bbc48288e68cd4717e83cd22025-08-20T02:50:13ZengElsevierEJC Paediatric Oncology2772-610X2024-12-01410020310.1016/j.ejcped.2024.100203Potential of non-FDG PET radiotracers for paediatric patients with solid tumoursLeonor Teles0Nelleke Tolboom1Sabine L.A. Plasschaert2Alex J. Poot3Arthur J.A.T. Braat4Max M. van Noesel5Princess Maxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Corresponding author.Princess Maxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Department of Radiology and Nuclear Medicine, University Medical Center Utrecht/Wilhelmina Children’s Hospital, Heidelberglaan 100, Utrecht 3584 CX, the NetherlandsPrincess Maxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the NetherlandsPrincess Maxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Department of Radiology and Nuclear Medicine, University Medical Center Utrecht/Wilhelmina Children’s Hospital, Heidelberglaan 100, Utrecht 3584 CX, the NetherlandsPrincess Maxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Department of Radiology and Nuclear Medicine, University Medical Center Utrecht/Wilhelmina Children’s Hospital, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands; Department of Nuclear Medicine, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, the NetherlandsPrincess Maxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Division Imaging & Cancer, University Medical Center Utrecht, Utrecht 3584 CX, the NetherlandsMolecular imaging with positron emission tomography (PET) offers significant potential for improving diagnostic accuracy, staging and treatment monitoring in paediatric solid tumours, by using radiopharmaceuticals more specific than [18F]fluorodeoxyglucose ([18F]FDG). While non-[18F]FDG tracers have already improved diagnostic abilities in adult solid cancers such as prostate and neuroendocrine tumours, their use in the paediatric population has been underexplored. This narrative review summarises clinical evidence regarding the use, advantages, and limitations of these more specific PET tracers in paediatric patients. In neuroblastoma, [18F]mFBG, [18F]F-DOPA, and SSTR-targeting peptides stand out as the most evolved and promising tracers for the clinical setting, with encouraging results regarding feasibility, safety and detection rates. SSTR-targeting peptides have also consistently outperformed other imaging methods (both conventional and functional) and carry the benefits of theragnostic applications. For brain tumours, amino acid-based tracers in general stand out due to their ability to surpass the blood-brain barrier/blood-tumour barrier (BBB/BTB) and their specific accumulation in malignant tissue. Other paediatric solid tumours, such as sarcoma and bone tumours, suffer from a clear lack of clinical evidence that should be addressed in the near future. The studies performed to date show high accuracy, evident prognostic value, and significant clinical impact of non-[18F]FDG tracers in paediatric patients with solid tumours. However, prospective studies with longer follow-up times are warranted to provide high-level evidence regarding the impact of these tracers on patient management and prognosis, to consolidate the encouraging results obtained so far. Further research and international collaboration will be essential to overcome current challenges related to low incidence of paediatric solid tumours, logistical barriers and concerns about radiation exposure.http://www.sciencedirect.com/science/article/pii/S2772610X24000631Paediatric solid tumoursNuclear medicinePositron emission tomographyRadiotracersTheragnosticsRadioimmunotherapy |
| spellingShingle | Leonor Teles Nelleke Tolboom Sabine L.A. Plasschaert Alex J. Poot Arthur J.A.T. Braat Max M. van Noesel Potential of non-FDG PET radiotracers for paediatric patients with solid tumours EJC Paediatric Oncology Paediatric solid tumours Nuclear medicine Positron emission tomography Radiotracers Theragnostics Radioimmunotherapy |
| title | Potential of non-FDG PET radiotracers for paediatric patients with solid tumours |
| title_full | Potential of non-FDG PET radiotracers for paediatric patients with solid tumours |
| title_fullStr | Potential of non-FDG PET radiotracers for paediatric patients with solid tumours |
| title_full_unstemmed | Potential of non-FDG PET radiotracers for paediatric patients with solid tumours |
| title_short | Potential of non-FDG PET radiotracers for paediatric patients with solid tumours |
| title_sort | potential of non fdg pet radiotracers for paediatric patients with solid tumours |
| topic | Paediatric solid tumours Nuclear medicine Positron emission tomography Radiotracers Theragnostics Radioimmunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2772610X24000631 |
| work_keys_str_mv | AT leonorteles potentialofnonfdgpetradiotracersforpaediatricpatientswithsolidtumours AT nelleketolboom potentialofnonfdgpetradiotracersforpaediatricpatientswithsolidtumours AT sabinelaplasschaert potentialofnonfdgpetradiotracersforpaediatricpatientswithsolidtumours AT alexjpoot potentialofnonfdgpetradiotracersforpaediatricpatientswithsolidtumours AT arthurjatbraat potentialofnonfdgpetradiotracersforpaediatricpatientswithsolidtumours AT maxmvannoesel potentialofnonfdgpetradiotracersforpaediatricpatientswithsolidtumours |